1 / 16

Transverse Myelitis

Transverse Myelitis. Emily O. Jenkins MD, PGY3 AM Report 12.18.09. Transverse Myelitis (TM) . Immune-mediated process results in neural injury to the spinal cord Varying degrees of weakness, sensory alterations and autonomic dysfunction

maddox
Télécharger la présentation

Transverse Myelitis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transverse Myelitis Emily O. Jenkins MD, PGY3 AM Report 12.18.09

  2. Transverse Myelitis (TM) • Immune-mediated process results in neural injury to the spinal cord • Varying degrees of weakness, sensory alterations and autonomic dysfunction • Up to half of idiopathic cases will have a preceding respiratory or gastrointestinal illness

  3. Spectrum of Neuroimmunologic Disorders Acute inflammatory demyelinatingpolyneuropathy 2. Chronic inflammatory demyelinatingpolyneuropathy 3. Acute disseminated encephalomyelitis 4. pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections

  4. TM: Incidence • Rare: Estimated between 1 and 8 cases per million people per year • 1400 new cases reported in US each year • Affects individuals of all ages with a bimodal peak between ages 10-19 and 30-39

  5. Presentation • 50% will lose all movement in legs • Nearly all have some degree of bladder dysfunction • 80-94% have numbness, paresthesias, or band-like dysethesias • Autonomic symptoms may include: urgency, incontinence, difficulty or inability to void, incomplete evacuation of bowel and/or bladder, sexual dysfunction • 80% of patients reach clinical nadir within 10 days of symptom onset • Thoracic spinal cord most typically involved in adults, cervical spinal cord in children

  6. TM Diagnostic Criteria

  7. Alternative diagnostic considerations • B12 deficiency: slowly progressive weakness, sensory ataxia, paresthesias • Radiation myelopathy • Hepatic myelopathy: rare neurologic complication of chronic liver disease with portal hypertension • Decompression sickness: complication of deep sea diving • Neurolathyrism: prolonged consumption of grass or chickling pea; slowly developing paraparesis with paresthesias; no treatment • Konzo: acute spastic paraparesis from high exposure to cyanogenic compounds in diets containing insufficiently processed bitter cassava

  8. Etiology • Acquired alteration in the innate or acquired immune system • Cellular injury and dysfunction • Infectious trigger: infectious agent triggers breakdown of immune tolerance for self-antigens • TM and ADEM: Superantigen-mediated activation of T lymphocytes • Suspected that multiple immune system components contribute to observed dysfunction including T and B lymphocytes, macrophages, and NK cells • Mechanism of injury also probably involves multiple pathways including T lymphocyte killing of neural cells, cytokine injury, activation of toxic microglial pathways, immune-complex deposition, and apoptosis

  9. Diseases associated with TM

  10. Distinguishing TM and GBS

  11. TM and MS • TM can be the presenting feature of MS • Patients ultimately diagnosed with MS are more likely to have: • asymmetric clinical findings • predominant sensory symptoms with relative motor sparing • MRI findings extending over fewer than two spinal segments • abnormal brain MRI • oligoclonal bands

  12. Pathology

  13. Treatment • No consensus guidelines • Mainstays include: • corticosteroids: no randomized trials • plasmapheresis: moderate to severe cases, or those who do not respond to steroids after 3-5 days • Pulse dose IV cyclophosphamide • CSF filtration therapy: spinal fluid is filtered for inflammatory factors (not available in US) • For severe, refractory cases: 2 year course of azothioprine, methotrexate, mycophenolate, or oral cyclophosphamide

  14. Prognosis • Most will have monophasic disease • Up to 20% will have recurrent inflammatory episodes within the spinal cord • Significant recovery is unlikely if no improvement by 3 months

  15. Recurrence • Predictors of recurrence: • Multifocal lesions within the spinal cord • Demyelinating brain lesions • CSF oligoclonal bands • Mixed connective tissue disorder • SS-A antibodies • Persistently high IL-6 levels in CSF: thought to lead to high NO production and subsequent neural injury • Predictors of poor outcome: • Initial complaint of back pain • Rapid progression to maximal symptoms within hours of onset • Spinal shock • 14-3-3 protein, a marker of neuronal injury, in CSF during acute phase

More Related